Ding X Q, Dolu V, Hadac E M, Holicky E L, Pinon D I, Lybrand T P, Miller L J
Center for Basic Research in Digestive Diseases, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA.
J Biol Chem. 2001 Feb 9;276(6):4236-44. doi: 10.1074/jbc.M003798200. Epub 2000 Oct 24.
Affinity labeling is a powerful tool to establish spatial approximations between photolabile residues within a ligand and its receptor. Here, we have utilized a cholecystokinin (CCK) analogue with a photolabile benzoylphenylalanine (Bpa) sited in position 24, adjacent to the pharmacophoric domain of this hormone (positions 27-33). This probe was a fully efficacious agonist that bound to the CCK receptor saturably and with high affinity (K(i) = 8.9 +/- 1.1 nm). It covalently labeled the CCK receptor either within the amino terminus (between Asn(10) and Lys(37)) or within the third extracellular loop (Glu(345)), as demonstrated by proteolytic peptide mapping, deglycosylation, micropurification, and Edman degradation sequencing. Truncation of the receptor to eliminate residues 1-30 had no detrimental effect on CCK binding, stimulated signaling, or affinity labeling through a residue within the pharmacophore (Bpa(29)) but resulted in elimination of the covalent attachment of the Bpa(24) probe to the receptor. Thus, the distal amino terminus of the CCK receptor resides above the docked ligand, compressing the portion of the peptide extending beyond its pharmacophore toward the receptor core. Exposure of wild type and truncated receptor constructs to extracellular trypsin damaged the truncated construct but not the wild type receptor, suggesting that this domain also may play a protective role. Use of these additional insights into molecular approximations provided key constraints for molecular modeling of the peptide-receptor complex, supporting the counterclockwise organization of the transmembrane helical domains.
亲和标记是一种强大的工具,可用于确定配体中光不稳定残基与其受体之间的空间近似关系。在此,我们利用了一种胆囊收缩素(CCK)类似物,其在第24位含有一个光不稳定的苯甲酰苯丙氨酸(Bpa),该位置紧邻该激素的药效基团域(第27 - 33位)。该探针是一种完全有效的激动剂,能以饱和且高亲和力(K(i) = 8.9 +/- 1.1 nm)与CCK受体结合。通过蛋白水解肽图谱分析、去糖基化、微纯化和埃德曼降解测序表明,它可共价标记CCK受体的氨基末端(在Asn(10)和Lys(37)之间)或第三个细胞外环(Glu(345))。将受体截短以去除残基1 - 30对CCK结合、刺激信号传导或通过药效基团内的一个残基(Bpa(29))进行的亲和标记没有不利影响,但导致Bpa(24)探针与受体的共价连接被消除。因此,CCK受体的远端氨基末端位于对接配体上方,将肽超出其药效基团向受体核心延伸的部分压缩。野生型和截短型受体构建体暴露于细胞外胰蛋白酶会损坏截短型构建体,但不会损坏野生型受体,这表明该结构域也可能起保护作用。利用这些对分子近似关系的额外见解为肽 - 受体复合物的分子建模提供了关键限制,支持跨膜螺旋结构域的逆时针组织。